Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for bl...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Weiss, Glen J., Tibes, Raoul, Blaydorn, Lisa, Jameson, Gayle, Downhour, Molly, White, Erica, Caro, Ivor, Von Hoff, Daniel D.
Format: Artigo
Jezik:Inglês
Izdano: PAGEPress Publications 2011
Teme:
Case Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4211514/
https://ncbi.nlm.nih.gov/pubmed/25386306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/dr.2011.e55
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items